Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, 21201, USA.
Am J Gastroenterol. 2012 Jun;107(6):835-47; quiz 848. doi: 10.1038/ajg.2012.66. Epub 2012 Apr 10.
Evidence-based treatment guidelines have been unable to provide evidence-based guidance on the effects of acupuncture for irritable bowel syndrome (IBS) because the only previous systematic review included only small, heterogeneous, and methodologically unsound trials. We conducted a new systematic review and meta-analysis of randomized controlled trials (RCTs) to estimate the effects of acupuncture for treating IBS.
MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, Cumulative Index to Nursing and Allied Health, and the Chinese databases Sino-Med, CNKI, and VIP were searched through November 2011. Eligible RCTs compared acupuncture with sham acupuncture, other active treatments, or no (specific) treatment, and evaluated acupuncture as an adjuvant to another treatment. Our outcomes were overall IBS symptom severity and health-related quality of life. Dichotomous data were pooled to provide a relative risk (RR) of substantial improvement after treatment, and continuous data were pooled to provide a standardized mean difference (SMD) in post-treatment scores between groups.
A total of 17 RCTs (N=1,806) were included. We found no evidence of an improvement with acupuncture relative to sham acupuncture on symptom severity (SMD=-0.11, 95% confidence interval (95% CI): -0.35 to 0.13; 4 RCTs) or quality of life (SMD=-0.03, 95% CI: -0.27 to 0.22; 3 RCTs). Because of the homogeneity of the results of the sham-controlled trials, results were unaffected by restriction to the four sham-controlled RCTs that used adequate randomization, blinding, and had few withdrawals/dropouts. Among RCTs that did not use a placebo control, acupuncture was more effective than pharmacological therapy (RR of symptom improvement=1.28, 95% CI: 1.12 to 1.45; 5 RCTs) and no (specific) treatment (RR = 2.11, 95% CI: 1.18 to 3.79; 2 RCTs). There was no difference between acupuncture and Bifidobacterium (RR=1.07, 95% CI: 0.90 to 1.27; 2 RCTs) or between acupuncture and psychotherapy (RR=1.05, 95% CI: 0.87 to 1.26; 1 RCT). Acupuncture as an adjuvant to another Chinese medicine treatment was statistically significantly better than the other treatment alone, in trials with a high risk of bias (RR=1.17, 95% CI: 1.02 to 1.33; 4 RCTs).
Sham-controlled RCTs have found no benefits of acupuncture relative to a credible sham acupuncture control on IBS symptom severity or IBS-related quality of life. In comparative effectiveness Chinese trials, patients reported greater benefits from acupuncture than from pharmacological therapies. Future trials may help clarify whether or not these reportedly greater benefits of acupuncture relative to pharmacological therapies are due entirely to patients' preferences for acupuncture or patients' greater expectations of improvement on acupuncture relative to drugs.
基于循证的治疗指南未能为针灸治疗肠易激综合征(IBS)的效果提供循证指导,因为之前唯一的系统性综述仅纳入了规模较小、异质性较大且方法学上不健全的试验。我们进行了一项新的系统评价和荟萃分析,以评估针灸治疗 IBS 的效果。
通过检索 MEDLINE、Cochrane 对照试验中心注册库、EMBASE、护理与联合健康累积索引以及中国的 SinoMed、CNKI 和 VIP 数据库,纳入 2011 年 11 月前发表的随机对照试验(RCT)。合格的 RCT 将针灸与假针灸、其他活性治疗或非(特定)治疗进行比较,并评估针灸作为另一种治疗的辅助治疗。我们的结局是 IBS 总体症状严重程度和健康相关生活质量。二分类数据采用相对风险(RR)表示治疗后显著改善的比例,连续性数据采用标准化均数差值(SMD)表示组间治疗后评分的差异。
共纳入 17 项 RCT(N=1806)。我们未发现针灸相对于假针灸在症状严重程度(SMD=-0.11,95%置信区间[95%CI]:-0.35 至 0.13;4 项 RCT)或生活质量(SMD=-0.03,95%CI:-0.27 至 0.22;3 项 RCT)方面有改善。由于假针灸对照试验结果的同质性,限制仅纳入采用充分随机化、盲法且脱落/退出率低的四项假针灸对照 RCT 后,结果不受影响。在未采用安慰剂对照的 RCT 中,针灸比药物治疗(RR 为症状改善的 1.28,95%CI:1.12 至 1.45;5 项 RCT)和非(特定)治疗(RR=2.11,95%CI:1.18 至 3.79;2 项 RCT)更有效。针灸与双歧杆菌(RR=1.07,95%CI:0.90 至 1.27;2 项 RCT)或心理治疗(RR=1.05,95%CI:0.87 至 1.26;1 项 RCT)之间无差异。在偏倚风险高的 RCT 中,针灸作为另一种中药治疗的辅助治疗明显优于单独使用其他治疗(RR=1.17,95%CI:1.02 至 1.33;4 项 RCT)。
假针灸对照 RCT 发现针灸在 IBS 症状严重程度或 IBS 相关生活质量方面与可信的假针灸对照相比无获益。在比较有效性的中国 RCT 中,患者报告针灸的获益大于药物治疗。未来的试验可能有助于阐明针灸相对于药物治疗的报告获益是否完全归因于患者对针灸的偏好,或患者对针灸改善的期望高于药物。